Search
Search Results
##search.searchResults.foundPlural##
-
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3727PDF: 2604HTML: 1635 -
CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL
4587PDF: 3765HTML: 374 -
ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
3000PDF: 1322HTML: 2835Figure 1: 201 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2600PDF: 1747HTML: 550 -
CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES
2300PDF: 2119HTML: 221 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
9345PDF: 6213HTML: 88096Fig.1b: 224Fig.1c: 224Fig.2a: 207Fig.2b: 206Fig.4: 228Fig.2c: 208Fig.3: 210Tab.1: 264Tab.2: 242Tab.3: 225Tab.4: 256Fig1a: 221 -
MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
2383PDF: 1366HTML: 17208Bassan Fig.1: 163Bassan Fig.2: 267Bassan Fig.4: 156Fig.3: 228 -
CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: DIAGNOSTIC TOOLS, PROPHYLAXIS AND THERAPY
4333PDF: 1987HTML: 5520Table 1: 236 -
HHVs AND LYMPHOPROLIFERATIVE DISORDERS
1477PDF: 860HTML: 3138 -
NOVEL DRUGS IN FOLLICULAR LYMPHOMA
5800PDF: 1570HTML: 1664Untitled: 260 -
IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?
3506PDF: 1337HTML: 2344Fi.1 Gritti.Rambaldi: 236 -
Follicular Lymphoma: A Clinicopathological Analysis from a Tertiary care Institute in Southern India
3540PDF: 824HTML: 3026Figure 1a and 1b: 173Figure 2: 181Figure 3: 200Figure 4: 180Figure 5: 185Tables 1-5: 169 -
CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA CAR-T and CLL
3876PDF: 1692HTML: 91 -
LYMPHOPROLIFERATIVE SYNDROMES ASSOCIATED WITH HUMAN HERPESVIRUS-6A AND HUMAN HERPESVIRUS-6B
3869PDF: 1649HTML: 864Figures . Eliassian: 255 -
BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL
1748PDF: 1140HTML: 167 -
TDT Positive High-Grade Lymphoma with Myc, BCL2 And BCL6 Rearrangements: a Review of Diagnosis and Treatment TDT POSITIVE HIGH-GRADE LYMPHOMA WITH MYC, BCL2 AND BCL6 REARRANGEMENTS.
2015PDF: 823HTML: 583 -
CURRENT KNOWLEDGE ON HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA
2698PDF: 1677HTML: 2453Table1: 214 -
CLINICAL ASPECTS AND THERAPY OF SPORADIC BURKITT LYMPHOMA
1360PDF: 616HTML: 4152 -
POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: ROLE OF VIRAL INFECTION, GENETIC LESIONS AND ANTIGEN STIMULATION IN THE PATHOGENESIS OF THE DISEASE
1421PDF: 487HTML: 18625Figure 1: 187Figure 2: 166Figure 3: 185Figure 4: 220Figure 5: 197 -
CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
4934PDF: 1862HTML: 2867Untitled: 254 -
ClinicaI Reversible Myelopathy in T-Cell Lymphoblastic Lymphoma Treated with Nelarabine and Radiotherapy: Report of a Case and Review of Literature of an Increasing Complication
2462PDF: 1035HTML: 1663Fig 1: 214Tab I: 240Cover Letter: 238 -
CROCIN PROMOTES APOPTOSIS IN HUMAN EBV-TRANSFORMED B-LYMPHOCYTE VIA INTRINSIC PATHWAY CROCIN PROMOTES APOPTOSIS IN EBV-TRANSFORMED LCL
1386PDF: 551HTML: 298 -
IMMUNOTHERAPY FOR EPSTEIN-BARR VIRUS-RELATED LYMPHOMAS
1279PDF: 626HTML: 6929 -
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA: NON-RANDOMIZED STUDY WITH A MAXIMUM FOLLOW-UP OF MORE THAN 22 YEARS
1611PDF: 944HTML: 2011Figure: 199Tables: 210ALL revision 1: 294response to reviewer: 203 -
DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA Downregulation of Scd-1 in Chronic Myeloid Leukemia
1468PDF: 1302HTML: 518 -
REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY Real-world Assessment of Myeloma Patients as Candidates for CAR-T Therapy
1679PDF: 689HTML: 1447 -
SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival
2156PDF: 886HTML: 362 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1530PDF: 1373HTML: 114







